MARKET

NSPR

NSPR

Inspiremd
NASDAQ
1.250
+0.010
+0.81%
After Hours: 1.240 -0.01 -0.80% 17:26 12/01 EST
OPEN
1.250
PREV CLOSE
1.240
HIGH
1.325
LOW
1.220
VOLUME
34.61K
TURNOVER
0
52 WEEK HIGH
3.750
52 WEEK LOW
0.8064
MARKET CAP
10.42M
P/E (TTM)
-0.5504
1D
5D
1M
3M
1Y
5Y
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists
Series to feature leading experts discussing the current and future trends in the carotid treatment marketTEL AVIV, Israel, Nov. 28, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for...
GlobeNewswire · 3d ago
InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium
TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEIT...
GlobeNewswire · 11/15 21:05
InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
- Generated 38.8% growth in CGuard™ revenue year-over-year - - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 - - Announced strategic partners...
GlobeNewswire · 11/08 12:00
InspireMD GAAP EPS of -$0.58 beats by $0.15, revenue of $1.43M beats by $0.03M
Seekingalpha · 11/08 10:07
InspireMD Q3 EPS $(0.58) Beats $(0.73) Estimate, Sales $1.43M Beat $1.40M Estimate
Benzinga · 11/08 09:20
-- Earnings Flash (NSPR) INSPIREMD Posts Q3 Revenue $1.4M, vs. Street Est of $1.6M
-- Earnings Flash (NSPR) INSPIREMD Posts Q3 Revenue $1.4M, vs. Street Est of $1.6M
MT Newswires · 11/08 07:25
BRIEF-InspireMD To Report Third Quarter 2022 Financial Results On November 8, 2022, And Provide Corporate Business Update
Reuters · 10/25 14:21
InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference
TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcathet...
GlobeNewswire · 09/13 20:05
More
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Webull offers kinds of InspireMD Inc stock information, including NASDAQ:NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.